- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
May 31, 2018
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of Px Pulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.
Dr. Larry Corey, who leads the HIV Vaccine Trials Network (HVTN), explains just how the AMP studies, HVTN 702 and HVTN 705 will each, in different ways, advance what we know about how to develop a vaccine for HIV.
Then, IAVI’s Dr. Kundai Chinyenze talks about efforts to ready all the powers that be for a possible success, so that new tools work in the real world as well as they do in a clinical trial.
And two deeply experienced advocates, Bill Snow and Matthew Rose, talk about engaging with the science and preparing for research results. Hosted and produced by Jeanne Baron
Listen to the full podcast (27:11).
Highlights
- Intro (2:19)
- Larry Corey makes a case for investment in vaccine research (2:30)
- Larry Corey on antibody-mediated prevention, HVTN 702 & HVTN 705 (7:43)
- Kundai Chinyenze on planning right for future rollout (7:00)
- Matthew Rose and Bill Snow share their take on the state and future of vaccine research (6:32)
- Bill Snow on history, advocacy and research literacy (2:25)
Additional Resources
- The Stories of HIV Vaccines in 2018 – From science to stakeholder engagement
- HIV Vaccine Introductory Factsheet
- HIV Vaccines 101 PowerPoint Presentation
- The Rise of Broadly Neutralizing Antibodies, a blog post by Bill Snow
- AVAC HIV Prevention Glossary
- AVAC and partners’ HVAD materials
- HIV-Specific Neutralizing Antibodies: Targets and research status
- HIV Vaccine Efficacy Trials: A surge of activity
- Prevention Research and Oral PrEP Rollout
- Vaccine Efficacy Trials Pipeline
- Total Vaccine Spending by Area, 2016
- Top AIDS Vaccine Funders, 2016
- Vaccine and Antibody Trial Participant Recruitment, 2018
- Develop Long-term Solutions to End the Epidemic: No Shortcuts
More Px Pulse
For more episodes of Px Pulse, click here.